European CRO Nuvisan acquires parts of Galderma R&D capabilities

11 September 2018

GMP News

The NUVISAN GROUP, one of Europe´s leading CRO´s focused on early stage drug development for the life science industry, signed an agreement with NESTLÉ SKIN HEALTH/ GALDERMA to take over parts of the R&D capacities in Sophia-Antipolis (France).

The GALDERMA R&D site in Sophia-Antipolis which opened in 2006 is the world’s largest research and development center focused on medical and cosmetic solutions for the skin. The new capabilities will strengthen Nuvisan’s core service lines in Bioanalysis, Clinical Trial Supplies and Pharmaceutical Analytics as well as enhancing the portfolio by adding GMP-API synthesis and formulation capability for prescription drugs and cosmetics. Nuvisan intends to start its operations in Sophia Antipolis in October 2018.

Headquartered in Germany, Nuvisan Pharma Services is a fully integrated Contract Research Organization and pharmaceutical service provider with an almost 40-years track record of serving clients’ needs in early and late clinical development. Nuvisan started operations as the privately owned contract research institute, LAB in 1979 and has been performing clinical pharmacological and pharmacokinetic studies ever since.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more